Literature DB >> 10204950

Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis.

P Hernigou1, F Beaujean, J C Lambotte.   

Abstract

We have evaluated bone-marrow activity in the proximal femur of patients with corticosteroid-induced osteonecrosis and compared it with that of patients with osteonecrosis related to sickle-cell disease and with a control group without osteonecrosis. Bone marrow was obtained by puncture of the femoral head outside the area of necrosis and in the intertrochanteric region. The activity of stromal cells was assessed by culturing fibroblast colony-forming units (FCFUs). We found a decrease in the number of FCFUs outside the area of osteonecrosis in the upper end of the femur of patients with corticosteroid-induced osteonecrosis compared with the other groups. We suggest that glucocorticosteroids may also have an adverse effect on bone by decreasing the number of progenitors. The possible relevance of this finding to osteonecrosis is discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10204950     DOI: 10.1302/0301-620x.81b2.8818

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  88 in total

1.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.

Authors:  Christopher C Dvorak; Clarisa R Gracia; Jean E Sanders; Edward Y Cheng; K Scott Baker; Michael A Pulsipher; Anna Petryk
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

2.  Osteogenic abilities of bone marrow stromal cells are not defective in patients with osteonecrosis.

Authors:  Jeong Joon Yoo; Won Seok Song; Kyung-Hoi Koo; Kang Sup Yoon; Hee Joong Kim
Journal:  Int Orthop       Date:  2008-02-19       Impact factor: 3.075

3.  One-stage hip arthroplasty and bone grafting for bilateral femoral head osteonecrosis.

Authors:  Lih-Yuann Shih; Yon-Cheong Wong; Hsin-Nung Shih
Journal:  Clin Orthop Relat Res       Date:  2008-07-22       Impact factor: 4.176

4.  Intralesional autologous mesenchymal stem cells in management of osteonecrosis of femur: a preliminary study.

Authors:  S Rastogi; S R Sankineani; H L Nag; S Mohanty; G Shivanand; K Marimuthu; R Kumar; L Rijal
Journal:  Musculoskelet Surg       Date:  2013-07-14

5.  Investigating clinical failure of core decompression with autologous bone marrow mononuclear cells grafting for the treatment of non-traumatic osteonecrosis of the femoral head.

Authors:  Lihua Liu; Fuqiang Gao; Wei Sun; Yunting Wang; Qingyu Zhang; Bailiang Wang; Liming Cheng; Zi-Rong Li
Journal:  Int Orthop       Date:  2018-04-13       Impact factor: 3.075

6.  Treating osteonecrosis with autologous bone marrow cells.

Authors:  Valérie Gangji; Jean-Philippe Hauzeur
Journal:  Skeletal Radiol       Date:  2010-03       Impact factor: 2.199

Review 7.  [Cell therapy in bone-healing disorders].

Authors:  M Jäger; P Hernigou; C Zilkens; M Herten; J Fischer; R Krauspe
Journal:  Orthopade       Date:  2010-04       Impact factor: 1.087

8.  Comment on: Osteogenic abilities of bone marrow stromal cells are not defective in patients with osteonecrosis.

Authors:  You-Shui Gao; Chang-Qing Zhang
Journal:  Int Orthop       Date:  2010-03       Impact factor: 3.075

9.  Hip osteonecroses treated with calcium sulfate-calcium phosphate bone graft substitute have different results according to the cause of osteonecrosis: alcohol abuse or corticosteroid-induced.

Authors:  Andrzej Sionek; Adam Czwojdziński; Jacek Kowalczewski; Tomasz Okoń; Dariusz Marczak; Marcin Sibiński; Marcin Złotorowicz; Jarosław Czubak
Journal:  Int Orthop       Date:  2018-03-17       Impact factor: 3.075

10.  Outcome of childhood leukaemia survivors and necrosis of the femoral head treated with autologous mesenchymal stem cells.

Authors:  T de Rojas; S Martínez-Álvarez; S Lerma-Lara; M Á Díaz; L Madero; M Ramírez
Journal:  Clin Transl Oncol       Date:  2017-09-12       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.